Key Highlights
● Elevance Health closed at $412.51 on 9 October 2026, up 2.88 per cent.
● Market data consensus target is $441.48, implying about 7.0 per cent upside.
● The second data set shows a mean of $451.48 and a median of $463.
● Barclays raised its target from $457 to $469 on 7 October.
Elevance Health (NYSE:ELV), one of the largest US health insurers and an S&P 500 member, closed at $412.51 on Friday 9 October 2026, a gain of 2.88 per cent on the day. Buy ratings outnumber Holds, and no analyst rates the stock Sell.
What Is the Latest Analyst Price Target?
Market data shows a consensus price target of $441.48 from 23 analysts with ratings in the last 12 months, with a high of $498.00 and a low of $360.00. Against the $412.51 close, the consensus target suggests upside of about 7.0 per cent.
The second data set, using third-party data from 22 analysts, shows a higher mean of $451.48, a median of $463.00, a high of $492.00 and a low of $393.00.
What Are Wall Street Analysts Saying?
Market data records 15 Buy and eight Hold ratings with no Sell ratings, giving a consensus rating of "Moderate Buy". The second data set shows a "Buy" consensus, with 12 Strong Buy, three Buy and seven Hold ratings.
Recent named actions on market data include Barclays (Andrew Mok), which raised its target from $457 to $469 on 7 October with an Overweight rating. A cluster of changes followed in mid-July. Truist Financial (David MacDonald) raised its target from $450 to $475 and TD Cowen (Ryan Langston) from $400 to $465 on 14 July. On 16 July, Guggenheim (Jason Cassorla) lifted its target from $399 to $455 and Robert W. Baird (Michael Ha) from $331 to $393, while Wells Fargo (Stephen Baxter) trimmed its target from $492 to $473 and Royal Bank of Canada (Ben Hendrix) from $439 to $424.
What Could Help the Stock Reach the Price Target?
Several brokers already hold targets well above the current price, including Truist at $475, Wells Fargo at $473 and Barclays at $469. If the shares were to move towards those levels, the consensus figure would be within reach.
What Could Prevent the Stock Reaching the Target?
Opinion is not unanimous. Eight analysts rate the stock Hold, and Goldman Sachs, Baird and Leerink hold targets around $393 to $395, below the current price. Royal Bank of Canada and Wells Fargo both reduced their targets in July, showing that not every revision has been upward.
Health insurers are sensitive to medical cost trends, regulatory and reimbursement changes and political developments, and any adverse surprise could cause analysts to revisit their estimates. The wide range from $360 to $498 on market data shows considerable disagreement about fair value.
What Should Investors Watch Next?
Investors may watch for further target revisions and any change in the ratings split.
Elevance Health's Positive Ratings and a Wide Target Range
Elevance Health closed at $412.51 on 9 October 2026 after a 2.88 per cent gain, with the market data consensus of $441.48 implying about 7.0 per cent upside. Targets range from $360 to $498 in the market data, showing wide disagreement about fair value.






Please wait processing your request...